Stock Report

All about this stock under one free report Last Updated: 27-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Parabolic Drugs Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: PARABDRUGS | BSE: 533211

₹5.50

up-down-arrow ₹-0.25 (-4.35%)

As on 25-Jan-2021IST

Market cap

info icon

₹35 Cr

Revenue (TTM)

info icon

₹0 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

-0

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -2.33 -31.95 -37.49
EBIT 98.87 14.29 13.75 19.20 14.26
Net Profit 98.89 15.28 10.43 -209.12 14.51
EPS 98.88 14.66 17.51 -209.12 14.51
Book Value -- -- -5.32 -190.75 -254.04
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-18Mar-17
EBIT-Margin info -232.53-157.99---69.23-133.86
Net Margin info -284.05-205.97-7,345.96-74.43-133.28
Return on equity info 0.00-46.76--0.000.00
Return on Capital info -52.21-39.50---31.96-47.01
Return on Assets info -32.08-29.24-11.78-12.89-20.53
Debt to Equity (x) info ----0.00-1.11-1.17

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-29.62
-45.35
-81.66
-19.30
Peer Median
--
15.21
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
--
--
--
--
Peer Median
10.86
9.89
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-11.78

Lower than Peers by 18.52

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
-11.78
-12.50
-20.19
-63.54
-36.61
Peer Median
6.74
5.28
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-69.01
-134.56
-494.00
-65.39
Peer Median
12.69
14.68
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-7,345.96

Lower than Peers by 7,354.82

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
-7,345.96
-74.31
-138.59
-639.24
-162.79
Peer Median
8.86
9.44
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-48.78
-116.95
-547.67
-146.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-1.52
-2.48
-67.38
-47.07
Peer Median
8.14
8.37
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

13.75

Lower than Peers by 3.50

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
13.75
49.50
73.44
-146.42
-1.30
Peer Median
17.24
22.09
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

10.43

Lower than Peers by 6.42

Year on year growth in profit after tax

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
10.43
47.25
77.73
-27.91
-187.95
Peer Median
16.85
9.35
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

17.51

Higher than Peers by 6.91

Year on year growth in earnings per share

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
17.51
47.25
77.73
-27.91
-187.95
Peer Median
10.60
5.26
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-5.30
-10.14
-140.64
-1,723.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-1.13
-1.18
-1.29
-3.06
Peer Median
0.04
0.29
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-0.17
-0.18
-0.35
-2.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.15

Lower than Peers by 1.57

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
0.15
0.20
0.28
0.30
0.81
Peer Median
1.72
1.68
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.15

Lower than Peers by 1.03

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
0.15
0.16
0.25
0.21
0.24
Peer Median
1.17
1.25
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-23.88

Lower than Peers by 31.75

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
-23.88
-4.97
-9.43
-3.47
-1.52
Peer Median
7.86
10.92
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
39.70
90.83
92.68
42.30
Peer Median
25.79
23.15
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
0.16
0.14
0.11
0.23
Peer Median
0.67
0.73
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
240.79
339.20
363.19
185.58
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
78.26
137.02
768.01
513.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
537.04
395.15
108.54
207.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
-217.99
81.07
1,022.66
490.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
--
--
--
--
Peer Median
40.16
31.85
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

-0.04

Lower than Peers by 4.20

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
-0.04
-0.05
-0.06
-0.04
-0.18
Peer Median
4.16
2.93
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
--
--
--
--
--
Peer Median
0.11
0.56
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-283.18

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
-283.18
-42.17
-14.13
-2.87
-7.99
Peer Median
--
23.55
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

35

Lower than Peers by 7,559

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-18
Mar-17
Mar-16
Mar-15
Parabolic Drugs
35
46
54
33
57
Peer Median
7,594
10,579
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...